FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562441316> ?p ?o ?g. }

• W2562441316 abstract "The taxanes (i.e., paclitaxel, docetaxel (DTX) and cabazitaxel) are microtubule (MT)-stabilizing drugs widely used to treat solid tumor malignancies. Their success is limited by the presence of intrinsic or acquired drug resistance. Understanding the molecular mechanisms of taxane resistance is a key to significantly improve clinical outcomes of taxane-based chemotherapy. In gastric cancer (GC), retrospective analysis of the TAX-325 trial revealed that the addition of docetaxel (DTX) to standard cisplatin/fluorouracil increased progression-free and overall survival, primarily only in intestinal subtype (INT) GC, suggesting that diffuse (DIF) GC may be intrinsically taxane resistant. In fact, our previous data supported this hypothesis; DIF GC cell lines had higher incidence (63%) of DTX resistance than INT GC cell lines (25%). Flow cytometric analyses showed negligible P-glycoprotein expression on the cell surface of all cell types, and accumulation of C 14 -labeled DTX in cells was observed in both sensitive and resistant GC cell lines. These results ruled out drug efflux as a possible mechanism that confers taxane resistance in DIF GC cells. Next, we used fluorescein-conjugated paclitaxel (Flutax) as a probe to investigate the affinity of taxanes to MTs. Live cell imaging showed strong binding of Flutax to MTs in a sensitive cell line at least for 60 minutes. In contrast, Flutax failed to stay bound to MTs in resistant GC cell lines,. In addition, discontinuous decoration of MTs with Flutax was seen in resistant but not in sensitive cell lines. Our observation suggests that MTs of resistant GC cell lines have lower affinity for taxanes, and there might be subtle structural changes of MTs. We are currently conducting the competition of Flutax/DTX to quantify the affinity of DTX in both types of GC cell lines. Because tubulin mutations have been reported in many taxane-resistant cell lines, we sequenced the different tubulin isotypes in GC cell lines using both Sanger and next generation sequencing. No mutations were identified. In addition, we did not see any significant changes in the expression of βIII-tubulin or tubulin post-translational modifications between the sensitive and resistant cell lines. Pathway analyses on the RNA-Seq datasets derived from the panels of sensitive and resistant cell lines before and after taxane treatment is ongoing to identify the key molecular events underlying taxane resistance.Taken together, our data indicate that new molecular pathway(s) or change of overall MT structure and/or function may contribute to the impaired taxane binding to MTs in resistant GC cells. Our study will lead us to novel mechanistic insights in intrinsic drug resistance, and will ultimately allow us to target key molecule(s) to overcome chemo-resistance, the key determinant to improve overall survival of patients. Citation Format: Katsuhiro Kita, Giuseppe Galletti, Kyle Cleveland, Prashant V. Thakkar, Ada Gjyrezi, Chao Zhang, Isabel Barasoain, J. Fernando Diaz, Doron Betel, Manish A. Shah, Paraskevi Giannakakou. Impaired taxane binding to MTs in intrinsically taxane resistant gastric cancer cells without β-tubulin mutation. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3600. doi:10.1158/1538-7445.AM2015-3600" @default.
• W2562441316 created "2017-01-06" @default.
• W2562441316 creator A5002647101 @default.
• W2562441316 creator A5027622610 @default.
• W2562441316 creator A5050726856 @default.
• W2562441316 creator A5056201275 @default.
• W2562441316 creator A5064080795 @default.
• W2562441316 creator A5064900701 @default.
• W2562441316 creator A5068746014 @default.
• W2562441316 creator A5071996306 @default.
• W2562441316 creator A5072909840 @default.
• W2562441316 creator A5089202777 @default.
• W2562441316 creator A5089966579 @default.
• W2562441316 date "2015-08-01" @default.
• W2562441316 modified "2023-09-26" @default.
• W2562441316 title "Abstract 3600: Impaired taxane binding to MTs in intrinsically taxane resistant gastric cancer cells without β-tubulin mutation" @default.
• W2562441316 doi "https://doi.org/10.1158/1538-7445.am2015-3600" @default.
• W2562441316 hasPublicationYear "2015" @default.
• W2562441316 type Work @default.
• W2562441316 sameAs 2562441316 @default.
• W2562441316 citedByCount "0" @default.
• W2562441316 crossrefType "proceedings-article" @default.
• W2562441316 hasAuthorship W2562441316A5002647101 @default.
• W2562441316 hasAuthorship W2562441316A5027622610 @default.
• W2562441316 hasAuthorship W2562441316A5050726856 @default.
• W2562441316 hasAuthorship W2562441316A5056201275 @default.
• W2562441316 hasAuthorship W2562441316A5064080795 @default.
• W2562441316 hasAuthorship W2562441316A5064900701 @default.
• W2562441316 hasAuthorship W2562441316A5068746014 @default.
• W2562441316 hasAuthorship W2562441316A5071996306 @default.
• W2562441316 hasAuthorship W2562441316A5072909840 @default.
• W2562441316 hasAuthorship W2562441316A5089202777 @default.
• W2562441316 hasAuthorship W2562441316A5089966579 @default.
• W2562441316 hasConcept C114851261 @default.
• W2562441316 hasConcept C121608353 @default.
• W2562441316 hasConcept C126322002 @default.
• W2562441316 hasConcept C133936738 @default.
• W2562441316 hasConcept C1491633281 @default.
• W2562441316 hasConcept C185592680 @default.
• W2562441316 hasConcept C2776694085 @default.
• W2562441316 hasConcept C2777292972 @default.
• W2562441316 hasConcept C2777511904 @default.
• W2562441316 hasConcept C2777899217 @default.
• W2562441316 hasConcept C2778239845 @default.
• W2562441316 hasConcept C2778707650 @default.
• W2562441316 hasConcept C2778971682 @default.
• W2562441316 hasConcept C2780192828 @default.
• W2562441316 hasConcept C2781190966 @default.
• W2562441316 hasConcept C502942594 @default.
• W2562441316 hasConcept C530470458 @default.
• W2562441316 hasConcept C54355233 @default.
• W2562441316 hasConcept C55493867 @default.
• W2562441316 hasConcept C71924100 @default.
• W2562441316 hasConcept C81885089 @default.
• W2562441316 hasConcept C86803240 @default.
• W2562441316 hasConcept C98274493 @default.
• W2562441316 hasConceptScore W2562441316C114851261 @default.
• W2562441316 hasConceptScore W2562441316C121608353 @default.
• W2562441316 hasConceptScore W2562441316C126322002 @default.
• W2562441316 hasConceptScore W2562441316C133936738 @default.
• W2562441316 hasConceptScore W2562441316C1491633281 @default.
• W2562441316 hasConceptScore W2562441316C185592680 @default.
• W2562441316 hasConceptScore W2562441316C2776694085 @default.
• W2562441316 hasConceptScore W2562441316C2777292972 @default.
• W2562441316 hasConceptScore W2562441316C2777511904 @default.
• W2562441316 hasConceptScore W2562441316C2777899217 @default.
• W2562441316 hasConceptScore W2562441316C2778239845 @default.
• W2562441316 hasConceptScore W2562441316C2778707650 @default.
• W2562441316 hasConceptScore W2562441316C2778971682 @default.
• W2562441316 hasConceptScore W2562441316C2780192828 @default.
• W2562441316 hasConceptScore W2562441316C2781190966 @default.
• W2562441316 hasConceptScore W2562441316C502942594 @default.
• W2562441316 hasConceptScore W2562441316C530470458 @default.
• W2562441316 hasConceptScore W2562441316C54355233 @default.
• W2562441316 hasConceptScore W2562441316C55493867 @default.
• W2562441316 hasConceptScore W2562441316C71924100 @default.
• W2562441316 hasConceptScore W2562441316C81885089 @default.
• W2562441316 hasConceptScore W2562441316C86803240 @default.
• W2562441316 hasConceptScore W2562441316C98274493 @default.
• W2562441316 hasLocation W25624413161 @default.
• W2562441316 hasOpenAccess W2562441316 @default.
• W2562441316 hasPrimaryLocation W25624413161 @default.
• W2562441316 hasRelatedWork W1971304289 @default.
• W2562441316 hasRelatedWork W1974625471 @default.
• W2562441316 hasRelatedWork W2004036687 @default.
• W2562441316 hasRelatedWork W2018363092 @default.
• W2562441316 hasRelatedWork W2029659626 @default.
• W2562441316 hasRelatedWork W2056399434 @default.
• W2562441316 hasRelatedWork W2065949950 @default.
• W2562441316 hasRelatedWork W2108929767 @default.
• W2562441316 hasRelatedWork W2141724777 @default.
• W2562441316 hasRelatedWork W2144564583 @default.
• W2562441316 hasRelatedWork W2264645855 @default.
• W2562441316 hasRelatedWork W2321346516 @default.
• W2562441316 hasRelatedWork W2498896558 @default.
• W2562441316 hasRelatedWork W2521781596 @default.
• W2562441316 hasRelatedWork W2743844182 @default.
• W2562441316 hasRelatedWork W2793508381 @default.
• W2562441316 hasRelatedWork W2924069641 @default.
• W2562441316 hasRelatedWork W3008471328 @default.

• next